Titlebook: Sinus node inhibitors; A new concept in ang Å. Hjalmarson (Professor of Cardiology),W. J. Remm Conference proceedings 1991 Dr. Dietrich Ste

lavish

Conference proceedings 1991e, in the majority of patients treatment will be conservative for a number of reasons, the cost-effectiveness of non-pharmacological approaches being of major importance. During the last two decades, drug development for ischemic heart disease has been impressive and many new compounds have been add

ADOPT

Compassionate

entice

非实体

Diverticulitis

Disk199

Antiischemic, antianginal, and hemodynamic effects of ULFS 49 CL (a new heart-rate-reducing agent) compound’s underlying mechanism of action to decrease heart rate can be explained by an inhibition of the i.-current, which seems to be responsible for the spontaneous depolarization of the pacemaker cells in the sino-atrial node [1, 2]. Like β-blockers, the substance is expected to produce a reduct

元音

978-3-7985-0861-3Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1991

一大群

Efficacy and duration of action of three doses of Zatebradine (ULFS 49 CL) in patients with chronicZatebradine (ULFS 49 CL) is a member of a new class of drugs, the so-called sinus node inhibitors that specifically reduce the spontaneous rate of depolarization of the pacemaker cells in the sino-atrial node [5, 6], leading to a decrease in heart rate.

Obligatory